# CVS Health Corporation (CVS) — InvestMoat Analysis

_Last analyzed: October 10, 2026_
_Asset class: equity · Canonical page: https://investmoat.com/stocks/cvs_

## Scores

| Dimension | Score (0–100) |
| --- | --- |
| Moat durability | 65 |
| Growth trajectory | 60 |
| Valuation | 77 |
| **Composite** | **66** |

Scores are computed deterministically from this asset’s data by the InvestMoat formula (see https://investmoat.com/llms.txt for methodology). Scores are not directly comparable across asset classes.

## Key stats

- **Ticker:** CVS
- **Market Cap:** ~$110B

## Moat

CVS owns all three links of the US drug and coverage chain: Aetna insurance (26M medical members), Caremark (one of three PBMs that process about 80% of US prescription claims) and roughly 9,000 retail pharmacies. The bundle is real and hard to copy, but each piece faces a sharper rival on its own, and PBM reform, already law in Medicare Part D, targets the most profitable link.

### Insurer, PBM and Pharmacy in One

CVS is the only company that runs a national insurer, a top-three PBM and the largest US pharmacy chain together. **The moat is the chain, not any one link**:

- **Caremark: One of the Big Three PBMs:** Caremark processed about 1.9 billion 30-day-equivalent prescription claims in 2025. With Express Scripts and Optum Rx it handles about 80% of US claims, according to Drug Channels. Q2 2026 Health Services revenue was $51.8B, up 11.5%. Scale lets Caremark negotiate rebates and pharmacy rates that small PBMs cannot.
- **Aetna: Repaired, Not Restored:** Aetna's medical benefit ratio fell to 87.4% in Q2 2026 from 89.9% a year earlier, and Health Care Benefits adjusted operating income rose to $2.43B from $1.31B. The repair came from pricing and exiting unprofitable markets, which is why Medicare Advantage membership slipped to 4.20M. For 2027 star ratings, more than 69% of Aetna MA members are in 4+ star plans, down from about 81%.
- **Retail Pharmacy: The Physical Front Door:** About 9,000 CVS Pharmacy locations sit within a short drive of most Americans and fill prescriptions for Caremark and Aetna members as well as rivals' members. Pharmacy and Consumer Wellness revenue was $33.8B in Q2 2026, up 0.7%, with adjusted operating income up 10.2% as store closures and rival bankruptcies concentrated volume.

**Moat verdict:** CVS's one strong pillar is the insurer-PBM-pharmacy bundle; every other pillar is a real advantage that Cigna or UnitedHealth matches. AI can automate pharmacy and claims operations, which helps a cost-focused integrated operator, but the main risk to the moat is PBM regulation, not AI.

### Top competitors

- **[UnitedHealth Group (UNH)](https://investmoat.com/stocks/unh):** Insurer plus Optum Rx pharmacy benefits.
- **Cigna Group (CI):** Express Scripts pharmacy benefits.
- **Walgreens:** Retail pharmacy.

## Growth

Q2 2026 (reported August 5, 2026) revenue was $106.1B, up 7.3%, with adjusted EPS of $2.58 versus $1.81. Health Services (Caremark) revenue grew 11.5% to $51.8B. Health Care Benefits (Aetna) revenue grew 3.5% to $37.5B while the medical benefit ratio improved to 87.4% from 89.9% and adjusted operating income nearly doubled. Pharmacy and Consumer Wellness revenue was flat at $33.8B. Management raised FY2026 adjusted EPS guidance to $7.90-$8.10 from $7.30-$7.50 and operating cash flow guidance to at least $11.5B, against FY2025 adjusted EPS of $6.75 on $402.1B of revenue.

- **Revenue CAGR estimate:** 3-6%
- **Primary type:** market share
- **Margin trend:** expanding
- **Key risk (moderate):** Part D delinking is already law (signed February 3, 2026) and is in the base. The pending risk is that the same flat-fee, full pass-through model is extended to commercial and employer plans, or that states ban PBM ownership of pharmacies, before 2028, cutting Caremark's spread and rebate income across the book that carries about half of CVS revenue.
- **Drivers:**
  - Health Services (Caremark) — Q2 2026 revenue $51.8B, +11.5% YoY; 473M pharmacy claims, +0.9% (stable)
  - Health Care Benefits (Aetna) — Q2 2026 revenue $37.5B, +3.5% YoY; medical membership 26.0M vs 26.7M; MA 4.20M vs 4.24M; more than 69% of MA members in 4+ star plans for 2027, down from about 81%, which trims 2028 bonus payments (stable)
  - Pharmacy and Consumer Wellness — Q2 2026 revenue $33.8B, +0.7% YoY; same-store sales +2.6% (stable)
- **Score derivation:** Base about 61 (3-6% CAGR, midpoint 4.5%) + 0 trajectory (Caremark, Aetna and retail all held stable: Caremark revenue +11.5% in Q2 2026 but claims only +0.9% and no prior-period segment rate on file) + 4 expanding margin (Aetna benefit ratio down 250bps YoY; adjusted operating income up in all three segments) - 5 moderate risk (commercial PBM reform still pending; Part D delinking is already in the base) = about 60.

## Valuation

At $86.16 (October 9, 2026 close) CVS sits about 53% of the way from the $65 bear to the $105 base, at about 10.8× the $7.90-$8.10 FY2026 adjusted EPS guide. The base assumes about 12× roughly $8.75 of 2027 EPS, an inferred figure (the guide midpoint plus about 9% from continued Aetna margin repair), not company guidance; 12× sits below Elevance's roughly 15× because a bigger share of CVS earnings is exposed to PBM reform. It is below the Street mean of about $116 because commercial PBM reform and Aetna's lower 2027 star ratings cap the multiple. The score is the formula at $86.16 on a $65 / $105 / $135 ladder.

| Multiple | Value | Note |
| --- | --- | --- |
| P/E (FY2026 adj. guide) | ~10.8× | $7.90-$8.10 adjusted EPS, raised August 5, 2026 |
| Price / Sales | ~0.27× | On the at-least-$414B FY2026 revenue guide |
| Dividend yield | ~3.1% | $2.66 annual dividend |

CVS trades at a low-teens-or-below multiple because the market prices each segment's worst case at once: PBM reform for Caremark, Medicare Advantage policy for Aetna and secular decline for retail. Earnings are recovering fast from the 2024-2025 Aetna trough, which is what the base pays for. _(as of October 2026)_

## Price scenarios

### Bear — $65

PBM reform cuts Caremark's economics, Aetna's lower 2027 star ratings trim 2028 bonuses, and EPS stalls near $8 at an 8× multiple.

- Congress or the states extend Part D-style delinking and full pass-through to commercial plans, or ban PBM ownership of pharmacies, cutting Health Services adjusted operating income
- Aetna's MA medical benefit ratio climbs back toward 89% as cost trend outruns 2027 pricing
- Retail pharmacy reimbursement keeps falling faster than front-store and volume gains, pushing Pharmacy and Consumer Wellness income lower

### Base — $105

Aetna's margin repair continues into 2027, Caremark absorbs reform with contract changes, and the stock re-rates to about 12× roughly $8.75 of 2027 EPS.

- FY2026 adjusted EPS lands in or above the $7.90-$8.10 range and 2027 estimates rise on Aetna margin
- Caremark renews its large clients through 2027 with pass-through pricing models that hold segment income
- Aetna keeps more than 60% of MA members in 4+ star plans in the 2028 ratings, limiting the bonus loss

### Bull — $135

The integrated model proves its worth: Aetna margins return to target, Caremark grows through reform, and the market pays about 14× for EPS near $9.50.

- Aetna's medical benefit ratio settles in the mid-80s and Health Care Benefits earns its long-term margin target
- PBM reform lands as transparency rules that Caremark already meets, removing the overhang
- Retail consolidation after rival closures lifts pharmacy volume and margin

---

InvestMoat is a research and education framework. Nothing here is financial advice. Past performance does not guarantee future results.